Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection

Höroldt, B; Haydon, Geoffrey; O'Donnell, Katrina; Dudley, Tracey; Mutimer, David

doi:10.1111/j.1478-3231.2006.01272.x

Cited by 21 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this therapeutic regimen includes PegIFN, a drug that requires subcutaneous injections, which can reduce adherence to treatment. Furthermore, the combination of PegIFN/RBV can cause several adverse effects that can lead to early treatment discontinuation, especially in cirrhotic patients, and it is contraindicated for a substantial number of patients (since previous studies have determined that approximately 17% of HCV-infected patients in the general US population had at least one contraindication to its use) (26,27). …”

Section: Discussionmentioning

confidence: 99%

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Zanaga

Miotto

Mendes

et al. 2016

Braz J Med Biol Res

View full text Add to dashboard Cite

Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83–100%, without significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contraindications and can cause significant adverse events, which can reduce adherence and impair SVR rates. SOF plus RBV for 24 weeks is another treatment option, with SVR rates of 82–96% among patients without cirrhosis and 62–92% among those with cirrhosis. Finally, SOF plus DCV provides 94–97% SVR rates in non-cirrhotic patients, but 59–69% in those with cirrhosis. The addition of RBV to the regimen of SOF plus DCV increases the SVR rates in cirrhotic patients above 80%, and extending treatment to 24 weeks raises SVR to 90%. The ideal duration of therapy is still under investigation. For cirrhotic patients, the optimal duration, or even the best regimen, is still uncertain. Further studies are necessary to clarify the best regimen to treat HCV genotype 3 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Zanaga

Miotto

Mendes

et al. 2016

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…4,5 Thus, it is important for chronic hepatitis C patients to receive IFN-␣ treatment to prevent malignant transformation by eradicating hepatitis C virus. [6][7][8][9][10][11] However, IFN-␣-induced thrombocytopenia often leads to dose reduction or discontinuation of IFN-␣ therapy. In particular, it is difficult to treat patients with advanced cirrhosis by IFN-␣ because often these patients also have severe thrombocytopenia.…”

Section: Introductionmentioning

confidence: 99%

Interferon-α2b–induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes

Yamane

Nakamura

Suzuki

et al. 2008

Blood

View full text Add to dashboard Cite

show abstract

“…Sustained virological response (SVR) after antiviral therapy may halt the progression of fibrosis with lower risk of developing HCC and improve survival (3). However, the SVR rates depend upon many host- and virus-related factors, including age, gender, obesity, IL-28B genotype, stage of liver fibrosis, HCV genotype, and baseline viral load (2, 4, 5). Treatment with pegylated interferon (Peg-IFN) and ribavirin (RBV) is considered as the standard treatment for hepatitis C associated with SVR in 40-50% and up to 80% of HCV genotype 1 and 2/3 (naïve) patients, respectively (6-8).…”

Section: Introductionmentioning

confidence: 99%

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

et al. 2013

View full text Add to dashboard Cite

BackgroundNot enough data are available about the effectiveness of consensus interferon (CIFN) among HCV genotype 3 patients who failed to respond to pegylated interferon and ribavirin.ObjectivesWe aimed to assess the efficacy and safety of CIFN and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy.Patients and MethodsThis open-label investigator-initiated study included 44 patients who received CIFN 15 µg /day plus ribavirin 800-1200 mg daily. In patients with an early virological response (EVR), the dose of CIFN was reduced to 15 µg thrice a week for further 36 weeks. Patients with delayed virological response continued to receive daily CIFN plus ribavirin to complete 48 weeks. The patients were considered “non-responders” if there were less than 2 log reduction in HCV RNA at 12 weeks and detectable HCV RNA at 24 weeks.ResultsTwenty-four patients (55%) were non-responders and 20 patients were relapsers to the previous treatment with pegylated interferon plus ribavirin (mean age 43.6 ± 9.4 years, males 25 (57%)). Nine patients were clinically cirrhotic (Child A). End of treatment virological response was achieved in 19 (43.1%) patients and sustained virological response (SVR) occurred in 12 (27.3%). Out of these 12 patients, eight were non-responders and four were relapsers to the previous treatment. Advanced fibrosis or clinical cirrhosis was associated with low SVR. Adverse events were fever, myalgia, anorexia, depression, and weight loss. Two patients received granulocyte colony stimulating factor for transient neutropenia. Seven patients were given erythropoietin to improve hemoglobin, and six were treated for mild depression. Two patients developed portosystemic encephalopathy.ConclusionsMore than one-quarter of treatment-experienced patients with HCV genotype 3 achieved SVR after re-treatment with consensus interferon plus ribavirin.

show abstract

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection

Abstract: The treatment of patients with advanced HCV is challenging, although many treated patients achieve SVR. Significant toxicity is experienced and there is treatment-related mortality. This balance of efficacy and toxicity needs to be considered before commencing treatment.

Cited by 21 publications

References 29 publications

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Interferon-α2b–induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Contact Info

Product

Resources

About